医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Manhattan Scientifics Seed Funded Imagion Bioscience & Owns 64 Million Shares IBX

2019年07月26日 AM02:55
このエントリーをはてなブックマークに追加


 

NEW YORK

Manhattan Scientifics (OTC; QB MHTX) announces its former wholly owned sub Imagion Bioscience (ASX:IBX) Receives A$2 million in R&D Tax Incentives from the Australian Government (ATO)

Bob Proulx, Executive Chairman of Imagion Biosystems, said: “We are very pleased to report to our shareholders that the tax incentive funds have been received and that the rebate came in higher than the A$1.7 million we originally expected. This cash infusion will significantly enhance our ability to advance the development of our ground-breaking diagnostic imaging technology which was recently designated by the U.S. Food and Drug Administration as a ‘Breakthrough Device’”.

About Manhattan Scientifics Inc.

Manhattan Scientifics is focused on the commercialization of disruptive technologies

Forward-looking statement:

This press release contains forward looking statements which are subject 5to a number of risks, assumptions and uncertainties. Mgt believes that purchase of our shares should be considered to be at the high end of the risk spectrum.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190725005680/en/

CONTACT

Marvin Maslow, Chairman: 917.923.3300

Manny Tsoupanarias, CEO : 917.688.4158

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • BioNet and Sartorius’ Company BIA Separations Collaborate on Production Process Development of mRNA Vaccines
  • ZAP Surgical Appoints Industry Veterans to Lead Chinese Market Expansion
  • ZAP Surgical 任命 业 内 资 深人士 领导 中国市 场 的拓展工作
  • 武田创造强劲的2021财年上半年业绩;受14个全球品牌的推动,增长态势有望进一步持续到财年年底
  • Seoul Semiconductor’s SunLike Natural Spectrum LEDs Selected by European Premium Lighting Brand LEDVANCE